Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy Volunteers

Neuropathic Pain Clinical Trial

Official title:

Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00971295
• Other study ID #: BIA-2093-125
• Status: Completed
• Phase: Phase 1
• First received: September 2, 2009
• Last updated: December 15, 2014
• Start date: October 2007
• Est. completion date: September 2008

Study information

• Verified date: December 2014
• Source: Bial - Portela C S.A.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Portugal: National Pharmacy and Medicines Institute
• Study type: Interventional

Clinical Trial Summary

The primary objective was to investigate whether multiple-dose administration of eslicarbazepine acetate affects the pharmacokinetics of metformin.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: September 2008
• Est. primary completion date: December 2007
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Male or female subjects aged between 18 and 45 years, inclusive.

• Body mass index (BMI) between 19 and 30 kg/m2, inclusive.

• Healthy as determined by pre-study medical history, physical examination, vital signs, complete neurological examination and 12-lead ECG.

• Negative tests for HBsAg, anti-HCVAb and HIV-1 and HIV-2 Ab at screening

• Clinical laboratory test results clinically acceptable at screening and admission to each treatment period.

• Negative screen for alcohol and drugs of abuse at screening and admission to each treatment period.

• Non-smokers or who smoke = 10 cigarettes or equivalent per day.

• Able and willing to give written informed consent.

• (If female) Not of childbearing potential by reason of surgery or, if of childbearing potential, she used one of the following methods of contraception: double barrier or intrauterine device.

• (If female) Negative urine pregnancy test at screening and admission to each treatment period.

Exclusion Criteria:

• Clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders.

• Clinically relevant surgical history.

• History of relevant atopy or drug hypersensitivity.

• History of alcoholism or drug abuse.

• Consumed more than 14 units of alcohol a week.

• Significant infection or known inflammatory process at screening or admission to each treatment period.

• Acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission to each treatment period.

• Used medicines within 2 weeks of admission to first period that may affect the safety or other study assessments, in the investigator's opinion.

• Used any investigational drug or participated in any clinical trial within 6 months prior to screening.

• Participated in more than 2 clinical trials within the 12 months prior to screening.

• Donated or received any blood or blood products within the 3 months prior to screening.

• Vegetarians, vegans or with medical dietary restrictions.

• Could not communicate reliably with the investigator.

• Unlikely to co-operate with the requirements of the study.

• Unwilling or unable to give written informed consent.

• (If female) Pregnant or breast-feeding.

• (If female) Of childbearing potential and she did not use an approved effective contraceptive method (double-barrier or intra-uterine device) or she used oral contraceptives.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Neuralgia
• Neuropathic Pain

Intervention

Drug:
• Metformin
850 mg metformin hydrochloride, once as oral single-dose and once after pre-treatment with once-daily dose of ESL 1200 mg for 6 days
• Eslicarbazepine acetate

Locations

Country	Name	City	State
Portugal	Human Pharmacology Unit (UFH)Section of Clinical Research (SIC), Department of Research & Development (DID), BIAL - Portela & Cª, SA,	Mamede do Coronado

Sponsors (1)

Lead Sponsor	Collaborator
Bial - Portela C S.A.

Country where clinical trial is conducted

Portugal, 

References & Publications (1)

Rocha JF, Vaz-da-Silva M, Almeida L, Falcão A, Nunes T, Santos AT, Martins F, Fontes-Ribeiro C, Macedo T, Soares-da-Silva P. Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects. Int J Clin Pharmacol Ther. 2009 Apr;47 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cmax - Maximum Observed Plasma Concentration	Maximum Observed Plasma Metformin Concentration	3 weeks	No
Secondary	Tmax - Time of Occurrence of Cmax	time of occurrence of maximum observed plasma metformin concentration	3 weeks	No
Secondary	AUC0-8 - Area Under the Plasma Concentration From Time Zero to Infinity	area under the plasma metformin concentration from time zero to infinity	3 weeks	No